Showing 478 news articles about New & experimental hepatitis C treatment

Filters Content type: Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

FDA approves Technivie for treatment of chronic hepatitis C genotype 4

Editor's pick
FDA
27 July 2015
Pharmaceutical industry

TAG Pipeline Report

Editor's pick
TAG
17 July 2015
New & experimental hepatitis C treatment

Gilead pills priced at $1,000 a day are found cost-effective

Editor's pick
Bloomberg
14 July 2015
New & experimental hepatitis C treatment

Leading Canadian researcher calls for inclusion of co-infected people in large HCV clinical trials

Editor's pick
CATIE
7 July 2015
Access to healthcare

The Medicines Patent Pool Releases Independent Feasibility Studies on Hepatitis C and Tuberculosis

Editor's pick
Medicines Patent Pool
7 July 2015
New & experimental hepatitis C treatment

FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data

Editor's pick
Wall Street Journal (blog)
29 June 2015
Hepatitis C treatment

AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

Editor's pick
AbbVie press release
24 June 2015
New & experimental hepatitis C treatment

Achillion partners with J&J to develop hepatitis C drugs

Editor's pick
Reuters
20 May 2015
New & experimental hepatitis C treatment

ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

Editor's pick
Viiv Healthcare press release
6 May 2015
Hepatitis C treatment

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Editor's pick
The Street
9 April 2015
New & experimental hepatitis C treatment

Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations

Editor's pick
Merck press release
9 April 2015
New & experimental hepatitis C treatment

At 50 Cents a Pill, Allergy Drug Could Best $1000 Sovaldi, Harvoni

Editor's pick
Healthline
9 April 2015
New & experimental hepatitis C treatment

FDA to review re-submitted Bristol-Myers hepatitis C drug

Editor's pick
Reuters
12 March 2015
New & experimental hepatitis C treatment

New hepatitis C treatments highly effective for HIV/HCV coinfected people

Editor's pick
HIVandHepatitis.com
26 February 2015
New & experimental hepatitis C treatment

Health News Review analysis of Reuters' coverage of new hepatitis C drugs

Editor's pick
Health News Review
13 February 2015
Access to healthcare

UNITAID: 2015 Hepatitis C medicines technology and market landscape

Editor's pick
UNITAID
13 February 2015
New & experimental hepatitis C treatment

FDA revokes breakthrough status for BMS hep C drug

Editor's pick
Fierce Biotech
11 February 2015
New & experimental hepatitis C treatment

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Editor's pick
Regulus Therapeutics press release
11 February 2015
New & experimental hepatitis C treatment

Promising data bodes well for all-Achillion hep C treatment

Editor's pick
Reuters
10 February 2015
New & experimental hepatitis C treatment

Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102

Editor's pick
Achillion press release
9 February 2015
New & experimental hepatitis C treatment

Merck says hepatitis C drugs to lose breakthrough status

Editor's pick
Reuters
5 February 2015
Pharmaceutical industry

AbbVie Inc stock drops after expectations for Viekira Pak fall short

Editor's pick
Bidness Etc
2 February 2015
Access to healthcare

Hepatitis C drug access: Europe is the new Africa

Editor's pick
HIV i-Base
30 January 2015
Access to healthcare

Petition: Equitable access to HCV drugs

Editor's pick
Petitionbuzz
30 January 2015